Valion Bio, Inc. (VBIO) stock forecast & analysis
1 analysis. Latest: .
Market Scanner’s AI analysis of Valion Bio, Inc. (VBIO), updated August 2026: Entolimod progress and U.S. government studies dominated VBIO's recent coverage amid significant technical downtrend.
Summary
Entolimod progress and U.S. government studies dominated VBIO's recent coverage amid significant technical downtrend.
Recent analyses for VBIO focused on developments concerning Entolimod, including U.S. government-funded studies for radiation injury and Ukraine's Ministry of Health advancing its review. The company's stock experienced a significant downward trend, with technical indicators suggesting oversold conditions. Insider buying activity was noted, alongside institutional holdings.
VBIO news & sentiment
News coverage focused on positive developments for Entolimod, including U.S. government studies and progress in Ukraine. The company was also noted as a significant premarket decliner and among most active stocks.
VBIO technical picture
The stock showed a strong downward trend, with the 10-day EMA well below longer-term SMAs. Momentum indicators suggested bearish conditions, and the price was below the lower Bollinger Band, indicating oversold territory.
Fundamentals
VBIO's recent earnings reports showed actual EPS exceeding estimates, particularly in the September 2023 quarter. Insider activity indicated net buying, with directors and officers making recent purchases. Institutional holders include Murchinson Ltd., Citadel Advisors Llc, and Sanctuary Advisors, LLC.
Factors discussed — upside
- Positive developments regarding Entolimod studies for radiation injury.
- Ukraine's Ministry of Health advancing Entolimod review.
- Insider net buying activity.
- Money Flow Index (MFI) indicating strong buying pressure.
- Actual EPS surprising positively against estimates in recent quarters.
Factors discussed — risks
- Significant downward trend in stock price.
- 10-day EMA significantly below 50-day and 200-day SMAs.
- RSI in oversold territory.
- MACD below its signal line, indicating bearish momentum.
- Price below the lower Bollinger Band.
- Entolimod developments
- Technical indicators
- Insider activity
- Earnings surprises
Summary updated .
Analyses
Recent VBIO.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Valion Bio, Inc.?
- The bull case centers on positive developments for Entolimod, including progress in U.S. government-funded studies for radiation injury and Ukraine's Ministry of Health advancing its review. Additionally, insider net buying activity and strong money flow index readings suggest potential upside.
- What are the risks for Valion Bio, Inc.?
- The bear case highlights a significant downward trend in the stock price, with key technical indicators such as the 10-day EMA, RSI, MACD, and Bollinger Bands suggesting oversold conditions and bearish momentum. Recent earnings have also shown negative EPS figures.
- Is Valion Bio, Inc. bullish or bearish?
- Recent AI analyses of Valion Bio, Inc. examined factors on both sides. Discussed upside: The bull case centers on positive developments for Entolimod, including progress in U.S. government-funded studies for radiation injury and Ukraine's Ministry of Health advancing its review. Additionally, insider net buying activity and strong money flow index readings suggest potential upside. Discussed risks: The bear case highlights a significant downward trend in the stock price, with key technical indicators such as the 10-day EMA, RSI, MACD, and Bollinger Bands suggesting oversold conditions and bearish momentum. Recent earnings have also shown negative EPS figures. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Valion Bio, Inc.?
- News coverage focused on positive developments for Entolimod, including U.S. government studies and progress in Ukraine. The company was also noted as a significant premarket decliner and among most active stocks.
- Bundles used
- gemini-low-v2
Sign in to read every VBIO.US report in the library
Each analysis includes the full reasoning, dissent, and decision rationale from the structured AI pipeline.